Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates

This quarterly report represents an earnings surprise of -3.92%. A quarter ago, it was expected that this company would post a loss of $0.65 per share when it actually produced a loss of $0.57, delivering a surprise of 12.31%. Biorestorative Therapies, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.04 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 16.67%. This compares to year-ago revenues of $0.03 million. The company has t ...